PHOTO
Doha: Every year, three out of 1000 births globally result in a baby being born with a serious condition called meconium aspiration syndrome (MAS). The condition happens when the baby passes their first bowel movement while still inside their mother’s womb and inhales the stool particles. The substance ends up inflaming and blocking the baby’s air passage, making it sometimes impossible to take in enough oxygen to breathe; resulting in a high risk of brain damage or in death.
Such was the case recently with baby Adam, who was born with MAS at Hamad Medical Corporation’s (HMC) Women’s Wellbeing and Research Center. “When we first laid eyes on Adam – everything seemed so normal. He was so beautiful! But then he started making gurgling noises. Our joy turned to despair as we only saw him for about few seconds before he was rushed out of the room in an incubator to the Newborn Intensive Care Unit (NICU),” said Adam’s mother.
It was quickly determined that the baby was suffering from severe respiratory issues and that the only option to save Adam’s life and reduce the risk of brain damage, would require the help of an advanced technology treatment called extracorporeal membrane oxygenation (ECMO). ECMO works by taking over the function of the lungs and sometimes the heart, and allowing the organs to rest and recover from a reversible condition like MAS.
Since Adam’s heart was still functioning properly, he only needed the ECMO machine to do the work for his lungs. Without ECMO, Adam only had a 10 percent chance of survival, but with it, his chances could go up by 85 percent.
Adam was immediately transferred to Sidra Medicine, the only hospital in Qatar and the Middle East to offer a neonatal respiratory ECMO service. The specialist women’s and children’s hospital’s Division of Neonatology recently installed the ECMO service to advance the neonatal and pediatric care of patients in the country.
During Adam’s ECMO process, blood was taken out of his body from the right side via a tube and circulated through the machine to remove carbon dioxide and add oxygen. It was then warmed back up to body temperature and returned to the right side of the heart, which then pumped the blood out to his body. This form of bypass, called venovenous, is used in conditions when only the lungs need support, and if the heart is working properly.
Commenting on the procedure, Dr. Mohammed Elkhwad, the Medical Director of the ECMO Neonatal program at Sidra Medicine said: “Baby Adam was rushed to Sidra Medicine where we immediately put him on the ECMO venovenous treatment course. This method is less invasive, which is better for the child. NICU babies treated with ECMO have the highest survival rates. The average ECMO treatment for MAS is about five days. Once a patient overcomes the acute phase, it allows time for the body and the lungs to gradually heal completely, thereby removing the risk of any long-term health problems.”
After four days on ECMO, Adam was weaned off and supported with a traditional ventilator. Soon afterwards, his breathing tube was removed, and in less than three weeks and after checking to ensure he had no issues in his brain, he was discharged. Today, Adam is a happy healthy baby with happy parents who are breathing easier too!
“We are so thankful that this amazing technology was available to him because it saved his life. We also cannot express enough gratitude to everyone across the healthcare network from HMC to the miracle workers of the ECMO team at Sidra Medicine, who worked on him around the clock and never left his side,” said Adam’s parents.
The neonatal respiratory ECMO program at Sidra Medicine provides both ECMO and Renal Dialysis.
It is part of a new multidisciplinary sub-specialty team that works closely with cardiology, intensive care, nephrology, diagnostic imaging, pathology, respiratory therapy and allied health. It includes a skilled team of local and international specialists, perfusionists, ECMO physicians, managerial, administrative and research staff.
Sidra Medicine has also launched a mobile ECMO unit that can be transported to other hospitals to help save the lives of babies who may have an urgent need for it. The mobile ECMO unit along with a specialist team, is able to go to any hospital in Qatar to immediately deliver treatment and care.
Dr. Abdulla Al Kaabi the Chief Medical Officer at Sidra Medicine said: “Sidra Medicine has pioneered several pediatric healthcare milestones within a span of one year. With the launch of the neonatal respiratory ECMO program, we are on a continuous trend to changing the landscape of advancing the specialist care of children and young people in the country. I am very proud of the team and our partnership with HMC which enabled the smooth and quick transfer of the patient to our hospital. All of us are happy that baby Adam’s life was saved and that we have the capacity and capability to save the lives of babies born with MAS.”
-Ends–
About Sidra Medicine
Sidra Medicine provides specialized healthcare to women, children, and young people from Qatar and around the world.
Established by Qatar Foundation for Education, Science and Community Development, Sidra Medicine embraces best practice medical education, innovative biomedical and clinical research and discovery, and exceptional patient and family focused care.
Sidra Medicine provides comprehensive specialist healthcare services for children and young people, as well as maternity and gynecology care for women. Some of its unique children’s specialist services include Cardiology, Neurology, Urology and Plastics & Craniofacial Reconstruction. It is also treats and cares for pregnant women with fetal complications.
The ultramodern healthcare organization is a testament to Qatar’s pioneering spirit and sustained commitment to its human and social development.
To access Sidra Medicine services, and learn more about our contribution to global healthcare, education and research, please visit www.sidra.org.
© Press Release 2019Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
